2024 ASCO® Annual Meeting Insights Hub
Meeting coverage & Vumedi’s exclusive highlights, all in one place.
Playback speed
10 seconds
ASCO® 2024 Insights: "KEYNOTE-942 Trial - 3-Year Update on mRNA-4157 & Pembro in Resected Melanoma"
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Jeffrey Weber
By
2024 ASCO® Annual Meeting Insights Hub
FEATURING
Jeffrey Weber
222 views
June 12, 2024
Chapters
KEYNOTE-942 Trial & mRNA-4157 Overview
00:00
Trial Design & Patient Eligibility
02:49
3-Year Treatment Results & Survival Data
04:22
Safety Profile & Biomarker Analyses
06:56
Login to view comments.
Click here to Login